Amgen announced the groundbreaking of its newest biomanufacturing facility, located in Holly Springs, North Carolina. The facility, expected to be operational by 2025, will support the growing demand for Amgen’s medicines that treat serious illnesses such as cancer and heart disease.
“Amgen is adding to North Carolina’s strong economic growth with the addition of its newest manufacturing plant to our already robust biomanufacturing ecosystem,” said Roy Cooper, Governor of North Carolina. “We welcome Amgen’s choice to build a state-of-the-art facility in our world-renowned Research Triangle region, bringing more than 350 high-quality new jobs to our state.”
Amgen’s facility will utilize new technologies that maximize efficiency and help ensure the ability to produce a broad range of medicines that Amgen offers to patients. The new facility will also be built to exacting environmental standards, consistent with the company’s goal of reducing water usage and waste and achieving carbon neutrality by 2027. Construction management and design services for this new state-of-the-art facility are being led by Integrated Project Services, LLC.
“For over four decades, Amgen has been an innovative leader in the manufacturing of complex biologics. Our commitment to continuous improvement and our significant investments in new technologies have enabled us to further accomplish our mission to serve patients while science rapidly evolves,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “We are delighted to be building our newest facility in North Carolina, a major hub for biopharmaceutical innovation.”
Amgen’s selection of North Carolina was driven, in part, by access to diverse talent. Amgen is a founding member of the OneTen Coalition, a coalition of 35 of the world’s largest, best-known companies which plans to use its resources to change the employment paradigm for Blacks in the United States. The Coalition aims to hire one million Black Americans into good-paying, family-sustaining jobs over the next ten years. To achieve this goal, Amgen will work with businesses, educational institutions, and training partners to better develop, retain and advance diverse talent, focusing on Black Americans without four-year college degrees.
Through the Amgen Foundation, the company is committed to inspiring the next generation of innovators in the Research Triangle region by partnering with local high schools to bring students the “Amgen Biotech Experience.” This program, one of many offered by the Amgen Foundation, provides teachers with the resources they need to bring a hands-on biotech learning experience into their classrooms. To date, this program has reached nearly 850,000 students around the world. The Amgen Foundation is the principal channel for Amgen’s corporate philanthropy and, to date, has contributed over $325 million to nonprofit organizations advancing excellence in science education and strengthening the communities where the company’s employees live and work.
Last year, Amgen was named one of the World’s Best Workplaces™ by Fortune magazine and Great Place to Work® and was also named by Forbes magazine as one of “America’s Best Employers for Diversity” for the fourth straight year. In 2022, Amgen was named to Newsweek magazine’s list of “America’s Most Responsible Companies” for the third consecutive year; JUST Capital’s list of “America’s Most JUST Companies” for the fifth consecutive year; Barron’s list of “America’s Most Sustainable Companies” for the second consecutive year; and the Human Rights Campaign Foundation’s list of “Best Places to Work for LGBTQ+ Equality” for the sixth consecutive year.
Amgen has approximately 24,000 employees worldwide. The company has manufacturing facilities in California, Ireland, Netherlands, Ohio, Puerto Rico, Rhode Island and Singapore.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World’s Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron’s.
